2024-09-18 - Analysis Report
## AMGN Stock Analysis Report

**Company Overview:** AMGN (Amgen Inc.) is a leading biotechnology company developing and manufacturing innovative medicines for patients with serious illnesses.

**Performance Analysis:**

1. **Performance vs. S&P 500:**
    * AMGN's cumulative return is 57.48%, while the S&P 500 (VOO) has a cumulative return of 88.56%. 
    * This indicates AMGN has underperformed compared to the S&P 500 by **-31.08%**.
    * The relative divergence indicates that AMGN is currently at the **46.08%** percentile of its historical performance relative to the S&P 500.

2. **Recent Price Movements:**
    * Closing price: 332.02
    * 5-day moving average: 331.95
    * 20-day moving average: 328.99
    * 60-day moving average: 326.02

    * The recent price movement indicates a slight upward trend with the price currently above all moving averages.

3. **Technical Indicators:**
    * **RSI:** 56.63, indicating a neutral to slightly overbought condition.
    * **PPO:** 0.15, suggesting potential for further upward momentum.
    * **Delta_Previous_Relative_Divergence:** 1.74, indicating a short-term upward trend.
    * **Expected Return:** 7.6%, reflecting the potential maximum 5-year expected return based on current investment amount.

4. **Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

* The most recent earnings (2024-08-07) were **1.39** EPS, exceeding analyst estimates by **0.04**. Revenue was **8.39B$**, surpassing estimates by **0.2B$**. 
* This indicates a positive trend in earnings and revenue, potentially signaling future growth.

**Conclusion:**

AMGN's recent performance has been characterized by modest growth, lagging behind the S&P 500. However, the recent earnings release demonstrates a strong performance exceeding expectations, suggesting a potential for positive future performance. Technical indicators also suggest a slightly overbought but overall positive trend. 

Overall, AMGN presents an opportunity for long-term growth, especially considering its strong earnings performance and a robust position in the biotechnology industry. However, it is crucial to monitor the stock's performance and potential risks due to its current relative underperformance compared to the broader market. 
